Investors / China / Lilly Asia Ventures
Lilly Asia Ventures
Venture capital · Shanghai, China · Asia Pacific
Lilly Asia Ventures is a biomedical venture capital firm. It invests long-term capital in entrepreneurs and companies developing products to treat diseases and improve human health.
Invests inHealthcare & Biotech
In its own wordsbiopharmaceuticalstherapeuticsmedical devicesdiagnosticshealthcare
Your fit with Lilly Asia Ventures
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsLilly Asia Ventures lists 60 checked portfolio companies on its own site and is named in 15 funding rounds, 3 of them as lead. Its most frequent entry is Series B, 57% of the companies with a known first round. Its largest themes are Healthcare & Biotech (96%), Fintech (2%) and Robotics & Hardware (2%). 56% of its companies are based in China. It invests most often alongside RA Capital, Qiming Venture Partners and ARCH Venture Partners.
Counts come from funding rounds that name Lilly Asia Ventures, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Lilly Asia Ventures' whole history. Rounds on record name 15 companies; its own site lists 60. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundLilly Asia Ventures does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 7% |
| Series A | 14% |
| Series B | 57% |
| Growth | 21% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 5 | 1 |
| '26 | 10 | 2 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 88th | 60 companies |
| Recent activity | 95th | 11 rounds in 12 months |
| Early stage | 54th | 7% of entries at pre-seed or seed |
| Evidence | 54th | 2% of companies confirmed by a round |
| Sector focus | 97th | 96% in its largest sector |
| Reach | 70th | 4 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| RA Capital | 8 |
| Qiming Venture Partners | 7 |
| ARCH Venture Partners | 4 |
| Foresite Capital | 4 |
| HSG | 4 |
| Casdin Capital | 3 |
| Decheng Capital | 3 |
| F-Prime Capital | 3 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers5490%
- No longer answers00%
- Points to another company610%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 96% | 15% |
| Fintech | 2% | 12% |
| Robotics & Hardware | 2% | 1% |
Co-investor network
who it backs companies with, and who they back togetherCompare Lilly Asia Ventures head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Lilly Asia Ventures| Date | Company | Stage |
|---|---|---|
| 31 Aug 2026 | Seed | |
| 13 Aug 2026 | Series B | |
| 26 Mar 2026 | Series B Led | |
| 13 Mar 2026 | Round | |
| 9 Feb 2026 | Series B Led | |
| 14 Jan 2026 | Series A | |
| 4 Dec 2025 | Series C+ Led | |
| 3 Oct 2025 | Series B |
Round details for Lilly Asia Ventures
Amounts, full round histories and every co-investor in Lilly Asia Ventures' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
60 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Airdoc develops and sells a device for children and teenagers to help control myopia | Healthcare & Biotech | Portfolio page | ||
| Akura Medical develops medical devices for treating venous thromboembolism | Healthcare & Biotech | Oct 2025Series B | Funding round | |
| Alebund is a biopharmaceutical company focused on developing innovative treatments for kidney diseases and related chronic diseases. | Healthcare & Biotech | Portfolio page | ||
| Allist is a biopharmaceutical company that develops and produces drugs, including treatments for non-small cell lung cancer. | Healthcare & Biotech | Portfolio page | ||
| Ansun Biopharma develops innovative therapeutics to address unmet medical needs in respiratory viral infections. | Healthcare & Biotech | Portfolio page | ||
| The company is dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with difficult-to-treat diseases, beginning with cancers. | Healthcare & Biotech | Portfolio page | ||
| The company develops, produces, and sells pharmaceutical preparations, specialty active pharmaceutical ingredients, and pharmaceutical key intermediates. | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Portfolio page | |||
| Avenzo Therapeutics develops next-generation oncology therapies to transform cancer treatment | Healthcare & Biotech | Sept 2025Series B | Funding round | |
| Bettapharma develops new drugs | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| Burning Rock Dx is a global diagnostics company focusing on applying next-generation sequencing technology in precision oncology. | Healthcare & Biotech | Portfolio page | ||
| Caldera Therapeutics is a clinical-stage biotechnology company developing a potential first-in-class bispecific antibody for inflammatory bowel disease and other immune-mediated diseases. | Healthcare & Biotech | Jan 2026Series A | Funding round | |
| CanSinoBIO is a biopharmaceutical company dedicated to providing global solutions for the prevention and treatment of infectious diseases through research and development, manufacturing and commercialization of vaccine products for human use. | Healthcare & Biotech | Portfolio page | ||
| Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. | Healthcare & Biotech | Portfolio page | ||
| The company develops breakthrough precise therapies using its own base editing system | Healthcare & Biotech | Portfolio page | ||
| Crown Bioscience provides services for translational oncology, including preclinical services, biomarker and bioanalysis services, and clinical biomarker services | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of oncology and hematological diseases. | Healthcare & Biotech | Portfolio page | ||
| The company develops innovative therapies using gene editing technology | Healthcare & Biotech | Portfolio page |
About this data
site last read 12 Nov 2026- Site
- lavfund.com
- Last read
- 12 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 9 Jan 2025
- Companies checked
- 60
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Lilly Asia Ventures' profile as data
Pull Lilly Asia Ventures' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/lavfund.com
# also
GET /v1/firms/lavfund.com/portfolio
GET /v1/firms/lavfund.com/coinvestors
GET /v1/firms/lavfund.com/news